Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.53
+0.44 (1.62%)
Dec 20, 2024, 4:00 PM EST - Market closed
Castle Biosciences Revenue
Castle Biosciences had revenue of $85.78M in the quarter ending September 30, 2024, with 39.50% growth. This brings the company's revenue in the last twelve months to $311.88M, up 62.43% year-over-year. In the year 2023, Castle Biosciences had annual revenue of $219.79M with 60.38% growth.
Revenue (ttm)
$311.88M
Revenue Growth
+62.43%
P/S Ratio
2.43
Revenue / Employee
$511,275
Employees
610
Market Cap
771.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.59B |
Avanos Medical | 681.50M |
Cytek Biosciences | 201.21M |
Standard BioTools | 155.90M |
Avid Bioservices | 150.45M |
Cronos Group | 111.23M |
AbCellera Biologics | 32.96M |
uniQure | 28.59M |
CSTL News
- 2 days ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 9 days ago - Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire
- 4 weeks ago - Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 4 weeks ago - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
- 6 weeks ago - Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - Business Wire
- 6 weeks ago - Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test - Business Wire
- 6 weeks ago - Use of Castle Biosciences' DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - Business Wire
- 6 weeks ago - Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript - Seeking Alpha